Japan launches first viral drug for esophageal cancer
This digest was compiled by AI from multiple sources — links to the originals are below.
Japan has begun commercial sales of the world's first oncolytic viral drug approved for esophageal cancer. The drug uses genetically modified viruses to selectively infect and destroy cancer cells without harming healthy tissue, administered directly into the affected area via endoscope. Approval is limited to patients with esophageal cancer for whom radical surgery or chemoradiotherapy is contraindicated.
Key Facts
- Japan began commercial sales of the world's first oncolytic viral drug approved for esophageal cancer.
- The drug uses genetically modified viruses that selectively infect and destroy cancer cells without harming healthy tissue.
- The drug is administered directly into the affected area using an endoscope.
- Approval is limited to patients with esophageal cancer for whom radical surgery or chemoradiotherapy is contraindicated.
- The drug was developed by Oncolys BioPharma, a Japanese biopharmaceutical company founded in 2004.
Drug Mechanism
The drug employs genetically modified viruses designed to selectively infect and destroy cancer cells while sparing healthy tissue. It is administered directly into the affected area using an endoscope.
Approval Scope
Approval is limited to patients with esophageal cancer for whom radical surgery or chemoradiotherapy is contraindicated. This represents a narrower group than the total number of esophageal cancer patients.
Development and Approval
The viral drug was developed by Oncolys BioPharma, a Japanese biopharmaceutical company founded in 2004. The therapy was created based on research originally conducted by a former professor at Okayama University. In December last year, the company filed an application with Japan's Ministry of Health, Labour and Welfare for approval to manufacture and sell the drug. In June this year, the drug received accelerated approval.
2 sources
Japan launches first viral drug for esophageal cancer
